View in EDS HTML Full Text PDF Full Text

Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.

Saved in:
Bibliographic Details
Title: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.
Authors: Aldred, Jason1 (AUTHOR) JAldred@selkirkneurology.com, Freire-Alvarez, Eric2 (AUTHOR), Amelin, Alexander V.3 (AUTHOR), Antonini, Angelo4 (AUTHOR), Bergmans, Bruno5,6 (AUTHOR), Bergquist, Filip7 (AUTHOR), Bouchard, Manon8 (AUTHOR), Budur, Kumar9 (AUTHOR), Carroll, Camille10 (AUTHOR), Chaudhuri, K. Ray11,12 (AUTHOR), Criswell, Susan R.13 (AUTHOR), Danielsen, Erik H.14 (AUTHOR), Gandor, Florin15,16 (AUTHOR), Jia, Jia9 (AUTHOR), Kimber, Thomas E.17,18 (AUTHOR), Mochizuki, Hideki19 (AUTHOR), Robieson, Weining Z.9 (AUTHOR), Spiegel, Amy M.9 (AUTHOR), Standaert, David G.20 (AUTHOR), Talapala, Saritha9 (AUTHOR)
Source: Neurology & Therapy. Dec2023, Vol. 12 Issue 6, p1937-1958. 22p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:21938253
DOI:10.1007/s40120-023-00533-1